AdaptHealth Corp. (NASDAQ:AHCO) Expected to Post Quarterly Sales of $643.13 Million

Brokerages expect AdaptHealth Corp. (NASDAQ:AHCOGet Rating) to announce $643.13 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for AdaptHealth’s earnings, with estimates ranging from $634.80 million to $653.00 million. AdaptHealth posted sales of $482.12 million during the same quarter last year, which would indicate a positive year over year growth rate of 33.4%. The firm is expected to report its next quarterly earnings report before the market opens on Monday, January 1st.

According to Zacks, analysts expect that AdaptHealth will report full year sales of $2.92 billion for the current financial year, with estimates ranging from $2.87 billion to $2.95 billion. For the next financial year, analysts expect that the firm will post sales of $3.25 billion, with estimates ranging from $3.14 billion to $3.35 billion. Zacks’ sales calculations are an average based on a survey of analysts that follow AdaptHealth.

AdaptHealth (NASDAQ:AHCOGet Rating) last released its quarterly earnings data on Thursday, February 24th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.25). The firm had revenue of $702.11 million for the quarter, compared to analyst estimates of $693.15 million. AdaptHealth had a net margin of 6.36% and a return on equity of 7.97%.

A number of analysts recently issued reports on the company. Truist Financial reduced their price objective on AdaptHealth from $30.00 to $20.00 in a research report on Friday, February 25th. Zacks Investment Research cut AdaptHealth from a “hold” rating to a “strong sell” rating in a research report on Wednesday, April 27th. SVB Leerink cut their price objective on AdaptHealth from $32.00 to $24.00 and set an “outperform” rating for the company in a research report on Wednesday, March 2nd. Deutsche Bank Aktiengesellschaft cut their price objective on AdaptHealth from $34.00 to $28.00 in a research report on Friday, February 25th. Finally, TheStreet cut AdaptHealth from a “c-” rating to a “d+” rating in a research report on Friday, April 29th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $25.14.

In other AdaptHealth news, Director Skyknight Capital Fund Ii, L.P bought 13,352 shares of AdaptHealth stock in a transaction dated Friday, March 4th. The shares were acquired at an average cost of $15.00 per share, with a total value of $200,280.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Stephen P. Griggs bought 32,342 shares of AdaptHealth stock in a transaction dated Thursday, March 3rd. The stock was acquired at an average cost of $15.44 per share, for a total transaction of $499,360.48. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 88,180 shares of company stock worth $1,351,923. Corporate insiders own 17.30% of the company’s stock.

Large investors have recently bought and sold shares of the business. Covestor Ltd acquired a new position in AdaptHealth during the 4th quarter worth $35,000. Nisa Investment Advisors LLC boosted its position in shares of AdaptHealth by 96.6% in the 1st quarter. Nisa Investment Advisors LLC now owns 1,710 shares of the company’s stock worth $27,000 after purchasing an additional 840 shares during the last quarter. US Bancorp DE boosted its position in shares of AdaptHealth by 142.4% in the 3rd quarter. US Bancorp DE now owns 1,939 shares of the company’s stock worth $46,000 after purchasing an additional 1,139 shares during the last quarter. Advisor Group Holdings Inc. boosted its position in shares of AdaptHealth by 306.5% in the 4th quarter. Advisor Group Holdings Inc. now owns 3,000 shares of the company’s stock worth $73,000 after purchasing an additional 2,262 shares during the last quarter. Finally, Islay Capital Management LLC bought a new position in shares of AdaptHealth in the 4th quarter worth $124,000. 83.68% of the stock is currently owned by hedge funds and other institutional investors.

AHCO opened at $11.43 on Tuesday. The stock has a market cap of $1.51 billion, a price-to-earnings ratio of 29.31, a PEG ratio of 0.23 and a beta of 0.47. AdaptHealth has a 1 year low of $11.40 and a 1 year high of $30.33. The company has a current ratio of 1.34, a quick ratio of 1.09 and a debt-to-equity ratio of 1.06. The stock has a fifty day moving average price of $15.42 and a 200 day moving average price of $19.19.

About AdaptHealth (Get Rating)

AdaptHealth Corp., together with its subsidiaries, provides home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps to patients for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.

Read More

Get a free copy of the Zacks research report on AdaptHealth (AHCO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AdaptHealth (NASDAQ:AHCO)

Receive News & Ratings for AdaptHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AdaptHealth and related companies with MarketBeat.com's FREE daily email newsletter.